Regulatory Approvals

FDA Clears sNDA for Taletrectinib With Updated DOR Data in ROS1+ NSCLC

By

Regulatory Approvals — FDA Clears sNDA for Taletrectinib With Updated DOR Data in ROS1+ NSCLC  OncLive

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. September 18, 2026.

By

Related Post

Regulatory Approvals

FDA Approves Finerenone for CKD Associated With Type 1 Diabetes

Regulatory Approvals

FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A

Regulatory Approvals

FDA Clears Robotic System for Endoscopic Procedures in the Colon

Financial News For All

Business Economy Finance

Commodities Price Update: Crude Oil $96.36, Brent $98.63, Copper $6.67, Coal $104.75 — Sep 18, 2026 8:00 AM EDT

Mergers & Acquisitions

FTC Requests Additional Information Regarding Fertitta, Caesars Merger

Mergers & Acquisitions

After one failed acquisition attempt, Lisata finds lifeline in Marea merger

Mergers & Acquisitions

Paramount-Warner Bros. Discovery Merger Clears FCC Foreign Ownership Review